Mellor R, Kearnes M, Lancaster K, McLauchlan L, Ritter A. Established tables and emergent huddles: exploring the processes of participation associated with the policy changes to opioid pharmacotherapy treatment in Australia in the context of COVID-19. Contemp Drug Probl. 2022 Sep 8;49(4):385-404. doi: 10.1177/00914509221123001
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Psychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; September 19, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 52(S47):453.
Quittner AL, Alpern AN, Wolin D, McLeod L, Downey C, Nelson L, Khandelwal N. Pysychometric analyses of a new GI symptom tracker for cystic fibrosis. Poster presented at the 31st Annual North American Cystic Fibrosis Conference; November 2, 2017. Indianapolis, IN. [abstract] Pediatr Pulmonol. 2017 Sep 19; 52(S47):S453. doi: 10.1002/ppul.23840
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.
Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008 Jan 1;11(1):32-43.
Santanello N, Norquist J, Nelsen L, Williams V, Hill CD, Bisgaard H. Validation of a pediatric caregiver diary to measure symptoms of postacute respiratory syncytial virus bronchiolitis. Pediatr Pulmonol. 2005 Jul 1;40(1):31-8.
Bray JW, Davis KL, Graver L, Schroeder D, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. J Behav Health Serv Res. 2005 Jan 1;32(3):282-93.
Enger C, Rothman KJ, Kylstra JW. Mortality rates during two years of treatment with intermittent inhaled tobramycin (TOBI) in cystic fibrosis. Pediatr Pulmonol. 1999 Sep 22;28(Suppl 19):339-40.